Researchers reported mRNA engineering of mesenchymal stem cells (MSCs) to create DC‑25, an allogeneic cell therapy designed to enhance immunomodulatory function and overcome limitations of autologous approaches. The work demonstrates that transient mRNA expression can program donor MSCs to improve persistence, activity and therapeutic signalling in immunotherapy contexts. Allogeneic cell therapies aim for off‑the‑shelf scalability but face rejection and variability challenges; mRNA offers a non‑genomic route to modulate cell behaviour temporarily. The study's findings could accelerate commercial interest in engineered allogeneic platforms and spur partnerships across cell‑therapy developers and mRNA technology providers.